<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: RhoA and RhoC have been proved to be over-expressed in many solid <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, including <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The reduction of RhoA and RhoC expression by <z:chebi fb="40" ids="33697">RNA</z:chebi> interference (RNAi) resulted growth inhibition of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="2" pm="."><plain>The present study was to evaluate the effect of silencing of RhoA and RhoC expression by RNAi on growth of human colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-bearing <z:mp ids='MP_0003815'>nude</z:mp> mice in vivo </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: To establish HCT116 cell transplantable model, the <z:mp ids='MP_0003815'>nude</z:mp> mice were subcutaneously inoculated with 1.0 × 10(7) HCT116 cells and kept growing till the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> xenografts reached 5-7 mm in diameter </plain></SENT>
<SENT sid="4" pm="."><plain>Then the mice were randomly assigned to three groups(seven mice in each group): (1) <z:mpath ids='MPATH_458'>normal</z:mpath> saline(NS) group, (2)replication-defective recombinant adenovirus carrying the negative control shRNA (Ad-HK) group and (3)replication-defective recombinant adenovirus carrying the 4-tandem linked RhoA and RhoC shRNAs (Ad-RhoA-RhoC) group </plain></SENT>
<SENT sid="5" pm="."><plain>Ad-HK (4 × 10(8) pfu, 30 ul/mouse), Ad-RhoA-RhoC (4 × 10(8) pfu, 30 ul/mouse) or PBS (30 ul/mouse) was injected intratumorally four times once every other day </plain></SENT>
<SENT sid="6" pm="."><plain>The weight and volumes of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> xenografts were recorded </plain></SENT>
<SENT sid="7" pm="."><plain>The levels of RhoA and RhoC <z:chebi fb="2" ids="33699">mRNA</z:chebi> transcripts and proteins in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> xenografts were detected by reverse quantitative transcription polymerase chain reaction (QRT-PCR) and immunohistochemical staining respectively </plain></SENT>
<SENT sid="8" pm="."><plain>The terminal deoxynucleotidyl transferase-mediated <z:chebi fb="0" ids="17625">dUTP</z:chebi> nick end labeling (TUNEL) assay was used to detect the <z:hpo ids='HP_0011420'>death</z:hpo> of cells </plain></SENT>
<SENT sid="9" pm="."><plain>RESULTS: The xenografts in mice could be seen at 5th day from the implantation of HCT116 cells and <z:hpo ids='HP_0000001'>all</z:hpo> had reached 5-7 mm in size at 9th day </plain></SENT>
<SENT sid="10" pm="."><plain>After injection intratumorally, the growth speed of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> xenografts in Ad-RhoA-RhoC group was significantly delayed compared with those in NS and Ad-HK group(P &lt; 0.05) </plain></SENT>
<SENT sid="11" pm="."><plain>The results of QRT-PCR showed that <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels of RhoA and RhoC reduced more in Ad-RhoA-RhoC group than those in NS and Ad-HK group </plain></SENT>
<SENT sid="12" pm="."><plain>The relative RhoA and RhoC <z:chebi fb="2" ids="33699">mRNA</z:chebi> transcripts were decreased to 48% and 43% respectively (P &lt; 0.05) </plain></SENT>
<SENT sid="13" pm="."><plain>Immunohistochemical analyses of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> xenograft sections also revealed the decreased RhoA and RhoC expression in Ad-RhoA-RhoC group </plain></SENT>
<SENT sid="14" pm="."><plain>TUNEL assay also showed higher <z:hpo ids='HP_0011420'>death</z:hpo> of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> xenograft tissue cells in Ad-RhoA-RhoC group </plain></SENT>
<SENT sid="15" pm="."><plain>CONCLUSION: Recombinant adenovirus mediated RhoA and RhoC shRNA in tandem linked expression may inhibit the growth of human <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumor</z:e> xenografts in vivo </plain></SENT>
<SENT sid="16" pm="."><plain>These results indicate that RhoA and RhoC might be potential targets for gene therapy in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>